BB Healthcare Trust PLC Issue of Equity (7862F)
November 18 2020 - 11:44AM
UK Regulatory
TIDMBBH
RNS Number : 7862F
BB Healthcare Trust PLC
18 November 2020
18 November 2020
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY,
TO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA,
JAPAN OR ANY MEMBER STATE OF THE EEA (OTHER THAN THE UNITED KINGDOM)
OR TO ANY NATIONAL, RESIDENT OR CITIZEN OF THE UNITED STATES, AUSTRALIA,
CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY MEMBER STATE OF
THE EEA (OTHER THAN THE UNITED KINGDOM OR TO PROFESSIONAL INVESTORS
IN IRELAND)
BB Healthcare Trust plc
Issue of Ordinary Shares
BB Healthcare Trust plc (the "Company") announces that it has today
issued 240,000 of its ordinary shares of one penny each ("Ordinary
Shares") pursuant to its block listing facility. The Ordinary Shares
will be issued at a price of 175.40 pence per Ordinary Share, a premium
to the prevailing net asset value ("cum income") per Ordinary Share.
Following the issue of Ordinary Shares, the Company's issued share
capital will comprise (486,194,689) Ordinary Shares and this is the
total number of Ordinary Shares with voting rights in the Company.
This figure (486,194,689) may be used by shareholders as the denominator
for the calculations by which they will determine if they are required
to notify their interest in, or a change to, their interest in the
Company under the Financial Conduct Authority's Disclosure Guidance
and Transparency Rules.
The Company's LEI is: 213800HQ3J3H9YF2UI82
For further information please contact:
Peel Hunt LLP
Liz Yong, Tom Pocock (Investment Banking)
Alex Howe, Ed Welsby (Sales)
Telephone: +44 (0) 207 418 8900
J.P. Morgan Cazenove
James Bouverat (Sales)
Telephone: +44 (0) 207 134 2224
Bellevue Asset Management (UK) Ltd.
Mark Ghahramani
Telephone: +44 (0) 203 326 2981
Disclaimer
This announcement does not constitute a prospectus relating to the
Company and does not constitute, or form part of, any offer or invitation
to sell or issue, or any solicitation of any offer to purchase or
subscribe for, any shares in the Company in any jurisdiction nor shall
it, or any part of it, or the fact of its distribution, form the basis
of, or be relied on in connection with or act as any inducement to
enter into, any contract therefore.
Peel Hunt LLP ("Peel Hunt") and J.P. Morgan Cazenove, which are authorised
and regulated by the Financial Conduct Authority, are acting for the
Company only in connection with the matters described in this announcement
and are not acting for or advising any other person, or treating any
other person as their client, in relation thereto and will not be
responsible for providing the regulatory protection afforded to clients
of Peel Hunt and J.P. Morgan Cazenove or advice to any other person
in relation to the matters contained herein.
The shares of the Company have not been and will not be registered
under the US Securities Act of 1933, and may not be offered or sold
in the United States absent registration or an applicable exemption
from the registration requirements. Moreover, the shares of the Company
have not been, nor will they be, registered under the applicable securities
laws of Australia, Canada, the Republic of South Africa, Japan or
any member state of the EEA (other than the United Kingdom). Further,
the Company will not be registered under the US Investment Company
Act of 1940, as amended. Subject to certain exceptions, the shares
of the Company may not be offered or sold in the United States, Australia,
Canada, the Republic of South Africa, Japan or any member state of
the EEA (other than the United Kingdom or to professional investors
in Ireland) or to, or for the account or benefit of, any national,
resident or citizen of the United States, Australia, Canada, the Republic
of South Africa, Japan or any member state of the EEA (other than
the United Kingdom or to professional investors in Ireland). The share
issuance programme, and the distribution of this announcement, in
other jurisdictions may be restricted by law and the persons into
whose possession this announcement comes should inform themselves
about, and observe, any such restrictions.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEFLFSRLVLTLII
(END) Dow Jones Newswires
November 18, 2020 11:44 ET (16:44 GMT)
Bellevue Healthcare (LSE:BBH)
Historical Stock Chart
From Apr 2024 to May 2024
Bellevue Healthcare (LSE:BBH)
Historical Stock Chart
From May 2023 to May 2024